Triptorelin pamoate: Phase III started

Debiopharm began an open-label, international Phase III trial to evaluate 2 intramuscular injections of a 6-month formulation of 22.5 mg triptorelin pamoate in 44 children with CPP. The product's active ingredient, triptorelin, is marketed in more than 80 countries for various indications, including advanced prostate cancer and CPP.

Watson has rights to triptorelin pamoate from Debiopharm in the U.S. and Canada, where it markets 1-, 3- and 6-month intramuscular formulations of the product as Trelstar to treat advanced prostate cancer. Ipsen, which has rights to triptorelin pamoate from Debiopharm outside the U.S., Iran, Israel, Japan and Sweden, markets 1-, 3- and 6-month formulations of the product as Decapeptyl for prostate cancer. ...